Drew Brees Partners With ARS Pharmaceuticals to Promote Neffy Epinephrine Nasal Spray

Former NFL quarterback Drew Brees has entered into a partnership with ARS Pharmaceuticals to launch a public awareness campaign regarding the management of severe allergies. The initiative focuses on educating the public about the risks associated with severe allergic reactions and the importance of preparedness for individuals living with these conditions.

Brees, who manages his own severe allergies, serves as the primary spokesperson for the campaign, which highlights the necessity of having accessible treatment options available at all times. The collaboration centers on the use of neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals for the emergency treatment of Type I allergic reactions, including anaphylaxis. Through this partnership, the company aims to provide information on how patients can integrate this needle-free delivery method into their daily safety routines. The campaign materials emphasize the importance of consulting with healthcare providers to develop comprehensive emergency action plans for those at risk of severe allergic episodes.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI